English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background and Aims:Recentlyit was reported that metabolic syndrome(MSis related to the large intestinal neoplasm. Thereforewe studied the relationship between MS and the colonic neoplasm using our original scoring systemi.e.the Gastrointestinal Metabolic Syndrome Score(GIMS. Patients and Methods:The participants were medical examinees who underwent total colonoscopy (CS from January to December 2006. Regarding body mass index blood pressure triglyceride high density lipoprotein cholesterol and fasting blood sugar results in each casewe referred to the criteria of MS and scored them from 0‑2(0:normal range1:aberration minor2:aberration. We added up the values to calculate the GIMS. We defined neoplastic lesions as adenoma or adenocarcinoma. When we found a neoplastic lesion in CSwe examined the case using the GIMS. Results:The average of GIMS in the neoplastic cases was significantly higher than that of the non‑neoplastic cases(p<0.05. Considering the higher rate in the efficiency and in the therapeutic patientswe decided that the positive standard was two or more scores in GIMS. Conclusions:GIMS is easily calculated and can be used to support diagnosis of large intestinal neoplasm in the future.(Kitakanto Med J 2008;58:183~187)

Usefulness of an Original Metabolic Syndrome Score in Large Intestinal Cancer Screening